AstraZeneca

Recent news

• Company notice
  SC 13G: Statement of acquisition of beneficial ownership by individuals-AstraZeneca PLC(9.9%),Alexion Pharmaceuticals, Inc.(9.9%)
  SEC · 2024/10/28
• Rating change
  AstraZeneca Target Raised to GBP117.00 From GBP115.00 by Deutsche Bank
  Dow Jones · 2026/9/15
• Rating change
  A Quick Look at Today's Ratings for AstraZeneca(AZN.US), With a Forecast Between $192.11 to $267.63
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• A Quick Look at Today's Ratings for AstraZeneca(AZN.US), With a Forecast Between $198.81 to $262.42
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• Rating change
  UBS Maintains AstraZeneca(AZN.US) With Buy Rating, Cuts Target Price to $204.7
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• Company notice
  Japan System Techniques: Initiation of COPD patient education joint program with Astrazeneca Co., Ltd. in Koryo-cho, Nara Prefecture - DELAYED
  JPX · 2024/7/29
• Company notice
  CSPC PHARMA: RECEIPT OF US$1.2 BILLION UPFRONT PAYMENT UNDER THE STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR THE DEVELOPMENT OF INNOVATIVE LONG-ACTING PEPTIDE MEDICINES
  HKEX · 2026/5/29
• Rating change
  A Quick Look at Today's Ratings for AstraZeneca(AZN.US), With a Forecast Between $216.27 to $273.05
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• Rating change
  Barclays Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $211.08
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Rating change
  Berenberg Bank Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $216.95
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• Rating change
  Citi Maintains AstraZeneca(AZN.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• BofA Securities Maintains AstraZeneca(AZN.US) With Buy Rating, Cuts Target Price to $218.15
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• Rating change
  Barclays Maintains AstraZeneca(AZN.US) With Buy Rating, Cuts Target Price to $211.54
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• Company notice
  LBT Innovations Ltd: ASTRAZENECA SALE & SERVICE CONTRACT UP TO A$4.1M
  N/A · 2024/8/7
• Company notice
  Monopar Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-AstraZeneca PLC(9.9%),Alexion Pharmaceuticals, Inc.(9.9%)
  SEC · 2024/10/28
• AstraZeneca Announces The Opening Of Its Newest Global Strategic Research And Development Center, In Kendall Square, Cambridge, Massachusetts; Co. Invests $1B To Grow Massachusetts Workforce By Over 50%
  Benzinga · 2026/10/6
• Rating change
  A Quick Look at Today's Ratings for AstraZeneca(AZN.US), With a Forecast Between $195.56 to $272.43
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• Rating change
  A Quick Look at Today's Ratings for AstraZeneca(AZN.US), With a Forecast Between $191.8 to $267.19
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• Berenberg Bank Maintains AstraZeneca(AZN.US) With Buy Rating, Cuts Target Price to $198.29
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• Citi Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $246.52
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• Rating change
  A Quick Look at Today's Ratings for AstraZeneca(AZN.US), With a Forecast Between $155.78 to $241.13
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• Rating change
  A Quick Look at Today's Ratings for AstraZeneca(AZN.US), With a Forecast Between $216.18 to $240.5
  \u5e02\u573a\u8d44\u8baf · 2026/9/7
• Rating change
  RBC Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Raises Target Price to $196.61
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• Rating change
  HSBC Maintains AstraZeneca(AZN.US) With Hold Rating, Raises Target Price to $188.75
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• Rating change
  Goldman Sachs Maintains AstraZeneca(AZN.US) With Buy Rating, Raises Target Price to $221.02
  \u5e02\u573a\u8d44\u8baf · 2026/9/10

Headlines are aggregated automatically and are not independently verified or edited by our team.